Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ALK I1171N ALK Y1278S |
| Therapy | Lorlatinib |
| Indication/Tumor Type | neuroblastoma |
| Response Type | predicted - resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ALK I1171N ALK Y1278S | neuroblastoma | predicted - resistant | Lorlatinib | Case Reports/Case Series | Actionable | In a retrospective analysis, a neuroblastoma patient harboring ALK Y1278S progressed on treatment with Lorbrena (lorlatinib) and was found to have acquired ALK I1171N (PMID: 38787533; NCT04477681). | 38787533 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (38787533) | Sequential analysis of cfDNA reveals clonal evolution in neuroblastoma patients receiving ALK targeted therapy. | Full reference... |